Home > Focus Areas > Prostate Cancer Connect > Post
  • Saved

4yr
Targeted fluorescent imaging of a novel FITC-labeled PSMA ligand in prostate cancer - PubMed

Targeted fluorescent imaging of a novel FITC-labeled PSMA ligand in prostate cancer - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34800176/

doi: 10.1007/s00726-021-03102-8. Online ahead of print. 1 Chinese PLA General Hospital, Chinese PLA Medical School, Beijing, 100853, China. 2 Department of Nuclear Medicine, Chinese PLA General Hospital, Beijing, 100853, China. 3 Department of Urology, Chinese PLA General Hospital, Beijing, 100853, China. 4 Chinese PLA General Hospital, Chinese PLA Medical School, Beijing, 100853, China.


Conclusion:A novel FITC-labeled PSMA ligand (PSMA-FITC) was synthesized by Fmoc solid-phase synthesis. PSMA-FITC has high sensitivity and specificity for PSMA( ) prostate cancer. The rapid targeting and high tumor-background contrast of PSMA-FITC proved that PSMA ligand-mediated prostate cancer-targeted fluorescence imaging has high potential value. This study provides a reference for the future development of PSMA nuclides and fluorescent dual-modal probes.

  • 4yr
    • Source: Amino Acids
    • Conclusion/Relevance: “PSMA-FITC is a promising probe and has important reference value for the development of PSMA fluorescent probes. In the future, it can be applied to obtain accurate tumor images for radical prostatectomy.”
    • The authors created a new fluorescein isothiocyanate (FITC)-labeled prostate-specific membrane antigen (PSMA) ligand (PSMA-FITC) and used to target fluorescence imaging of PSMA-positive prostate cancer.
    • “To test the tumor-targeting effect of PSMA-FITC, the affinity of the probe to PSMA was determined in vitro,” wrote the authors. “Results of show that the affinity is at the nanomolar level and that the affinity is better than that of the PSMA blocker ZJ43, which may be due to the benzene ring structure of the fluorescent group increasing the affinity for the PSMA ligand.”
    • PSMA-FITC is highly sensitive and specific for PSMA(+) prostate cancer, with the swift targeting and high tumor-background contrast of PSMA-FITC supporting the potential value of PSMA ligand-mediated prostate cancer-targeted fluorescence imaging.